← All stories
Tech

Did AstraZeneca's (LSE:AZN) Lung Cancer Data Just Reset The Blue-Chip Mood Today?

1 source ·1 article ·3h ago

Highlights AstraZeneca rose after disclosing results from late-stage lung cancer studies. The pharmaceutical group was cited among the supports for London's leading benchmark today. Oncology remains the largest contributor to the company's…

Covered by 1 outlet

All coverage · 1 article